# Genova

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genova

- Industry: Biotechnology
- Headquarters: Changzhou, China
- Website: www.genova-corp.com
- Latest round: Series A (May 24, 2016)
- Investors on record: 1

## About

Genova is a biotechnology company focused on developing and manufacturing innovative solutions for the pharmaceutical and healthcare sectors, enhancing medication efficacy and safety.Founded in 2014 and headquartered in Changzhou, China, Genova specializes in biotechnology products for pharmaceuticals. The company has undergone significant growth, raising USD 50.00 mn in its Series B funding round on June 21, 2024, from Tasly Holding Group. CEO Michael Moschewitz leads the firm, which has completed three major deals to date.Genova specializes in the development and manufacturing of cutting-edge biotechnology products aimed at addressing critical needs in pharmaceuticals and healthcare. The company’s core offerings include advanced drug formulations, manufacturing solutions, and contract development and manufacturing organization (CDMO) services. These products are designed to enhance the efficacy and safety of medications, addressing challenges faced by pharmaceutical companies in drug delivery and compliance. Genova serves a diverse clientele, which includes major pharmaceutical corporations and research institutions across North America, Europe, and parts of Asia. By leveraging their expertise in research and development, Genova has positioned its products as essential tools for enhancing therapeutic outcomes and streamlining production processes in the global market.Genova's revenue is generated primarily through a structured transaction model that encompasses B2B partnerships and direct contracts with pharmaceutical clients. The company engages in long-term collaborations with its clients, focusing on providing tailored manufacturing and development services to meet specific pharmaceutical needs. Transactions often involve negotiated contracts that establish pricing plans based on the volume and complexity of services, including exclusive agreements for flagship products. These partnerships allow Genova to secure consistent revenue streams while maintaining a robust pipeline of innovative solutions. The firm’s revenue framework is bolstered by its commitment to quality and performance, fostering strong relationships within the healthcare sector.Genova aims to utilize its recent funding to support the development of new biotechnology products and expand its market presence. The company is working on launching several new drug formulations, with release dates targeting late 2024. Additionally, Genova has plans to penetrate new geographic markets, specifically aiming to establish a stronger presence in Europe and parts of Asia by the end of 2025. The USD 50.00 mn raised in the Series B funding round will be pivotal in driving these initiatives, ensuring the company can effectively scale and meet growing demands.

## Funding rounds

- Series A, May 24, 2016 — BVCF Capital

## Investors

- BVCF Capital — Series A